BEVYXXA

Peak

betrixaban

NDAORALCAPSULEPriority Review
Approved
Jun 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
7

Clinical Trials (5)

NCT03613402N/AWithdrawn

BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding Outcomes

Started Sep 2018
0
Venous Thromboses
NCT03346083Phase 1Terminated

Study Evaluating Betrixaban in Pediatric Participants

Started Jul 2018
21 enrolled
VTE Prophylaxis
NCT02596100Phase 1Completed

A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations

Started Sep 2015
52 enrolled
Healthy
NCT03330457Phase 2Terminated

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing

Started Aug 2015
18 enrolled
Bleeding
NCT01583218Phase 3Completed

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Started Mar 2012
7,513 enrolled
Venous Thromboembolism (VTE)

Loss of Exclusivity

LOE Date
Mar 29, 2031
61 months away
Patent Expiry
Mar 29, 2031

Patent Records (5)

Patent #ExpiryTypeUse Code
9555023
Nov 7, 2026
U-1502
7598276
Nov 8, 2026
Substance
8557852
Sep 8, 2028
U-2030
8987463
Dec 28, 2030
Product
8404724
Mar 29, 2031
Product
U-2034